CEO Sergio Traversa Buys $828K of Relmada Stock in Open Market
RLMD has more than doubled off its 52-week low of $1.44.
Summary
Relmada Therapeutics CEO Sergio Traversa bought 200,000 shares for $828,000 in open-market purchases on September 9-10, 2026, increasing his direct holdings to 1.5 million shares.
Key Events · Ownership and Investor Activity · RLMD
-
CEO Open-Market Purchase
Sergio Traversa bought 200,000 shares for $828,000 in two transactions on September 9-10, 2026, at prices ranging from $4.03 to $4.22 per share.
-
Post-Transaction Holdings
Direct holdings increased to 1,500,000 shares following the purchases.
-
Context: Recent CMO Departure
The purchase follows the September 8, 2026 disclosure that Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended.
Analysis · RLMD · Life Sciences
CEO Sergio Traversa purchased 200,000 shares for $828,000 across two days at prices between $4.03 and $4.22. This is a real-money open-market buy, not an option exercise or grant, and it comes just days after the company disclosed the departure of its Chief Medical Officer – Urology. The purchase is modest relative to the company's size but carries weight because it is the CEO putting his own capital to work at current prices.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.5% of the 1993 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLMD was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $434.1M. The 52-week trading range was $1.44 to $8.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.